Here’s What Analysts Think About Pfizer Inc. (PFE)

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price target of $30.00. The same day, Bernstein analyst Courtney Breen reiterated a Hold rating on the stock, keeping the associated price target the same at $30.00.

Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock

Pfizer Inc. (NYSE:PFE) also received a rating update from BofA analyst Jason Gerberry on December 16, who slashed the price target on the stock to $27 from $28 while keeping a Neutral rating on the shares. The rating update came after Pfizer Inc. (NYSE:PFE) “notably called out” faster COVID-19 product erosion compared to previous guidance as part of its 2026 outlook call. Following the guidance call, the firm “modestly” reduced its 2026 Pfizer sales and EPS estimates along with its FY27 EPS estimates, and expects the planned obesity data updates from the Metsera acquisition to provide a better understanding of the company’s potential obesity differentiation.

Separately, on December 17, Pfizer Inc. (NYSE:PFE) announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV™ (enfortumab vedotin). It reported that PADCEV™ Plus Keytruda considerably improved survival for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility, with the trial meeting its primary endpoint and exhibiting statistically significant and clinically meaningful improvements in event-free survival (EFS), and overall survival (OS), a key secondary endpoint.

Management added that PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy that improves event-free and overall survival when used before and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.